Compare CTY & FSSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTY | FSSL |
|---|---|---|
| Founded | 2023 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.4M |
| IPO Year | 2026 | 2025 |
| Metric | CTY | FSSL |
|---|---|---|
| Price | $17.55 | $11.76 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $37.33 | N/A |
| AVG Volume (30 Days) | ★ 250.4K | 237.3K |
| Earning Date | 12-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 15.05% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $62.96 | N/A |
| Revenue Next Year | $7.47 | N/A |
| P/E Ratio | ★ N/A | $9.70 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.81 | $10.75 |
| 52 Week High | $22.65 | $14.49 |
| Indicator | CTY | FSSL |
|---|---|---|
| Relative Strength Index (RSI) | 41.04 | 50.13 |
| Support Level | $16.12 | $11.33 |
| Resistance Level | $21.98 | $11.91 |
| Average True Range (ATR) | 2.35 | 0.28 |
| MACD | -0.15 | -0.01 |
| Stochastic Oscillator | 25.44 | 40.63 |
City Therapeutics Inc is a clinical-stage biotechnology company developing the next generation of RNA interference (RNAi) therapeutics designed to silence the expression of disease-relevant proteins. Its current pipeline is focused on indications with unmet medical need, including thromboembolic diseases, Stargardt disease type 1 (Stargardt disease), and anemia of chronic disease.
FS Specialty Lending Fund is a United States-based externally managed, non-diversified, closed-end management investment company. The company's investment objectives are to generate current income and, to a lesser extent, long-term capital appreciation by investing mainly in private and public credit in a broad set of industries, sectors, and sub-sectors. Its investment policy is to invest mainly in a portfolio of secured and unsecured floating and fixed-rate loans, bonds, and other types of credit instruments, which, under normal circumstances, will represent at least eighty percent of the Company's total assets.